(MMI) announced today that it received FDA investigational device exemption (IDE) to study its microsurgery platform.

Robots have never felt as close to becoming a part of everyday life as they do today. Their widespread use now seems likely ...

The feasibility study, entitled REMIND, Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease, will ...

Microbot Medical ( ($MBOT) ) has issued an announcement. On November 5, 2025, Microbot Medical announced the limited commercial availability of ...

Microbot Medical (Nasdaq:MBOT) announced today that it began the U.S. commercial launch of its Liberty endovascular surgical ...

Company Completes the Required Infrastructure to Support the Introduction of LIBERTY® to the U.S. Market with the Hiring of the Core Commercial ...

Investing.com -- Microbot Medical Inc. (NASDAQ:MBOT) stock rose 5.8% Wednesday after the company announced the commercial availability of its LIBERTY® Endovascular Robotic System in the United States.

Humanoids are moving from labs to industry, enhancing efficiency and working alongside humans, not replacing them. Ethical, socially beneficial integration is key to trust and adoption.

Moonfire Ventures founder Mattias Ljungman discusses rapid advancements in A.I., the robotics revolution and Tesla's future ...

Dr. Jack Wagoner, associate chief medical officer at Northwestern Medicine Kishwaukee Hospital, with the da Vinci Xi robotic ...

Discover Novanta Inc.'s Q3 2025 earnings highlights, record revenue, robust growth in medical & robotics, and 2026 outlook.

In early 2025, Thomas Greer, director of Digital Platforms at Orion Medical (a disguised name), was trying to decide how Orion could best use two new digital platforms that supported virtual surgical ...